XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning Balance at May. 31, 2019 $ 637,899 $ 16,709 $ 213,583 $ (11,640) $ 419,247
Beginning Balance (in shares) at May. 31, 2019   104,433,178      
Exercise of options, RSUs and share-based compensation expense 34,679 $ 227 34,452    
Exercise of options, RSUs and share-based compensation expense (in shares)   1,415,348      
Issuance of shares under employee stock purchase plan $ 1,193 $ 7 1,186    
Issuance of shares under employee stock purchase plan (in shares) 43,156 43,156      
Net income $ 59,475       59,475
Other comprehensive income (loss) (8,069)     (8,069)  
Ending Balance at May. 31, 2020 725,177 $ 16,943 249,221 (19,709) 478,722
Ending Balance (in shares) at May. 31, 2020   105,891,682      
Exercise of options, RSUs and share-based compensation expense 39,680 $ 226 39,454    
Exercise of options, RSUs and share-based compensation expense (in shares)   1,410,948      
Issuance of shares under employee stock purchase plan $ 1,388 $ 6 1,382    
Issuance of shares under employee stock purchase plan (in shares) 38,406 38,406      
Issuance of shares for Megazyme acquisition $ 4,916 $ 20 4,896    
Issuance of shares for Megazyme acquisition (in shares)   127,268      
Net income 60,882       60,882
Other comprehensive income (loss) 8,334     8,334  
Ending Balance at May. 31, 2021 $ 840,377 $ 17,195 294,953 (11,375) 539,604
Ending Balance (in shares) at May. 31, 2021 107,468,304 107,468,304      
Exercise of options, RSUs and share-based compensation expense $ 13,208 $ 46 13,162 0 0
Exercise of options, RSUs and share-based compensation expense (in shares)   289,334      
Issuance of shares under employee stock purchase plan $ 1,876 $ 7 1,869 0 0
Issuance of shares under employee stock purchase plan (in shares) 43,456 43,456      
Net income $ 48,307 $ 0 0 0 48,307
Other comprehensive income (loss) (16,394) 0 0 (16,394) 0
Ending Balance at May. 31, 2022 $ 887,374 $ 17,248 $ 309,984 $ (27,769) $ 587,911
Ending Balance (in shares) at May. 31, 2022 107,801,094 107,801,094